Brind.

Revolution Medicines and Summit Therapeutics announced a collaboration on August 19, 2025, to evaluate combination therapies.

3 reports, 1 independent Updated Aug 19
Gone quiet
Reports
3
Developments
3
Repetition
33%

New informationRepeats or wire copies

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Revolution Medicines and Summit Therapeutics announced a collaboration on August 19, 2025, to evaluate combination therapies.

Who's involved

What this event is mainly about
Revolution Medicines (United States)Summit Therapeutics

How it developed

Newest first. Tap a step to see who reported it.
  1. Revolution Medicines and Summit Therapeutics are collaborating to evaluate combination therapies using RAS inhibitors and ivonescimab for targeted cancer treatment.Sub-event
  2. Collaboration between Revolution Medicines and Summit Therapeutics to evaluate combination therapies.1 source
  3. Collaboration formed between Revolution Medicines and Summit Therapeutics to evaluate drug combinations.

Keep exploring

The entities involved

Related events

Coverage

Newest first; wire copies grouped
  • Insider MonkeySummit Therapeutics Advances as Trial Outcomes and New Collaboration Drive Optimism Summit Therapeutics Inc. (NASDAQ:SMMT) is one of the 11 Best Short Squeeze Stocks to Buy Now. Following mixed resul
  • Unknown outlet
  • Unknown outlet